Since 2009, the Foundation Groupe Chèque Déjeuner is partner of the Foundation of the future, under the support of the applied medical research-related projects.
The Foundation of the Future is now an intrinsic part of French Mutuality. The Foundation is designing tomorrow’s medical practices, but is not forgetting today’s patients, in accordance with its Mutualist roots. The Foundation of the Future is the embodiment of the differentiation of mutual organizations, both for the public interest, and for innovation that benefits all.
Since its inception in 1987, the Foundation of the Future is able to grow and fulfill its mission to support medical applied research thanks to the commitment of its partners from the Mutualist and social economy such as Groupe Chèque Déjeuner.
In those 20 years, over 700 research projects were financed by the Foundation of the Future and have resulted in major discoveries such as deep brain stimulation in the treatment of the symptoms of Parkinson’s disease or the identification of the sentinel lymph node in colorectal cancer.
This partnership is based on yearly co-financing of a research project validated by the Scientific Council of the Foundation of the Future, with a maximum of 10,000 euros corresponding to half the project’s funding needs.
In 2012, the subsidy granted by the Foundation Groupe Chèque Déjeuner contributed to the development of the medical project led by Professor François Patto
To visit the Foundation of the Future website: click here
Development of a new surgical approach for the treatment of type 2 diabetes
Type 2 diabetes affects more than 2 million people in France, it has therefore become a major public health issue. It was observed that certain changes in the digestive system, specifically a gastrojejunal diversion, could reduce diabetes dramatically. But this major surgery is reserved for obese patients.
This is why Professor François Pattou (University of Lille 2 / Faculty of Medicine) is developing a mini-invasive endoscopic technique that could be used for non-obese diabetics treatment, thereby avoiding post operative complications.